Toxicity analysis of dose escalation from 75.6 Gy to 81.0 Gy in prostate cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 34, Issue 1, 2011, Pages 11-15

  Xu, Natalie ^a   Rossi, Peter J ^a   Jani, Ashesh B ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

dose escalation; outcomes; prostate cancer; radiotherapy; toxicity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGE; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DISEASE SEVERITY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GASTROINTESTINAL TOXICITY; GLEASON SCORE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; PATIENT SAFETY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RACE; RADIATION DOSE; RADIATION DOSE ESCALATION; RADIATION INJURY; RADIATION SAFETY; UROGENITAL TRACT DISEASE;

AGED; FOLLOW-UP STUDIES; GASTROINTESTINAL TRACT; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; SURVIVAL RATE; TREATMENT OUTCOME; UROGENITAL SYSTEM;

EID: 79951589568     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181cae8c6     Document Type: Article

References (33)

1. Leibel SA, Hanks GE, Kramer S. Patterns of care outcome studies: results of the national practice in adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1984;10:401-409. (Pubitemid 14110176)
2. Smit WG, Helle PA, Van Putten WL. Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose. Int J Radiat Oncol Biol Phys. 1990;18:23-29. (Pubitemid 20047386)
3. Scardino PT. The prognostic significance of biopsies after radiotherapy for prostatic cancer. Semin Urol. 1983;1:243-252.
4. Miller EB, Ladaga LE, el-Mahdi AM, et al. Reevaluation of prostate biopsy after definitive radiation therapy. Urology. 1993;41:311-316.
5. Crook J, Robertson S, Collin G, et al. Clinical relevance of transrectal ultrasound, biopsy, and serum prostate-specific antigen following external beam radiotherapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1993;27:31-37. (Pubitemid 23270654)
6. Babaian RJ, Kojima M, Saitoh M, et al. Detection of residual prostate cancer after external radiotherapy: role of prostate specific antigen and transrectal ultrasonography. Cancer. 1995;75:2153-2158.
7. Kuban DA, el-Mahdi AM, Schellhammer P. The significance of postirradia-tion prostate biopsy with long-term follow-up. Int J Radiat Oncol Biol Phys. 1992;24:409-414.
8. Hanks GE, Hanlon AL, Schultheiss TE, et al. Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys. 1998;41:501-510. (Pubitemid 28275077)
9. Zelefsky MJ, Fuks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys. 2002;53:1111-1116. (Pubitemid 34787844)
10. Cahlon O, Zelefsky MJ, Shippy A, et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys. 2008;71:330-337.
11. Zelefsky MJ, Cowen D, Fuks Z, et al. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer. 1999;85:2460-2468. (Pubitemid 29244857)
12. Zelefsky MJ, Yamada Y, Fuks Z, et al. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys. 2008;71:1028-1033.
13. Kuban DA, Thames HD, Levy LB, et al. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys. 2003;57:915-928. (Pubitemid 37324109)
14. Thames HD, Kuban DA, DeSilvio ML, et al. Increasing external beam dose for T1-T2 prostate cancer: effect on risk groups. Int J Radiat Oncol Biol Phys. 2006;65:975-981.
15. Bey P, Carrie C, Ginestet C, et al. French study of dose escalation from 66 to 80 GY with 3D-CRT in prostate cancer: results at 5 years. Int J Radiat Oncol Biol Phys. 2003;57:S272.
16. Dearnaley DP, Hall E, Lawrence D, et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer. 2005;92:488-498. (Pubitemid 40395529)
17. Shipley WU, Verhey LJ, Munzenrider JE, et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys. 1995;32:3-12.
18. Al-Mamgani A, van Putten WL, Heemsbergen WD, et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;72:980-988.
19. Pollack A, Zagars GK, Smith LG, et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol. 2000;18:3904-3911.
20. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097-1105. (Pubitemid 34787842)
21. Kuban D, Tucker S, Dong L, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:67-74. (Pubitemid 350251041)
22. Goldner G, Bombosch V, Geinitz H, et al. Moderate risk-adapted dose escalation with three-dimensional conformal radiotherapy of localized prostate cancer from 70 to 74 Gy: first report on 5-year morbidity and biochemical control from a prospective Austrian-German multicenter phase II trial. Strahl-enther Onkol. 2009;185:94-100.
23. The NCCN Clinical Practice Guidelines in Oncology Prostate Cancer (Version 2, 2009). 2009 National Comprehensive Cancer Network, Inc. Available at: http://www.NCCN.org. Accessed September 18, 2009.
24. Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys. 2000;47:13-47. (Pubitemid 30179675)
25. Dawson-Saunders B, Trapp RG. Basic and Clinical Biostatistics. East Nor-walk, CT: Prentice Hall; 2000.
26. Zelefsky MJ, Levein EJ, Hunt M, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:1124-1129. (Pubitemid 351296130)
27. Michalski JM, Winter K, Purdy JA, et al. Trade-off to low-grade toxicity with conformal radiation therapy for prostate cancer on Radiation Therapy Oncology Group 9406. Semin Radiat Oncol. 2002;12(suppl 1):75-80. (Pubitemid 34246073)
28. Michalski JM, Winter K, Purdy JA, et al. Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II. Int J Radiat Oncol Biol Phys. 2003;56:192-198. (Pubitemid 36403691)
29. Michalski JM, Winter K, Purdy JA, et al. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV. Int J Radiat Oncol Biol Phys. 2004;58:735-742.
30. Michalski JM, Winter K, Purdy JA, et al. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose level V. Int J Radiat Oncol Biol Phys. 2005;62:706-713. (Pubitemid 40779758)
31. Al-Mamgani A, Heemsbergen WD, Peeters ST, et al. Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2009;73:685-691.
32. Pollack A, Hanlon AL, Horwitz EM, et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys. 2006; 64:518-526. (Pubitemid 43083441)
33. Radiation Therapy Oncology Group (RTOG) Trial 04-15: A phase III randomized study of hypofractionated 3D-CRT/IMRT versus conventionally fractionated 3D-CRT/IMRT in patients with favorable risk prostate cancer. Available at: http://www.rtog.org.